TNX 3700
Alternative Names: TNX-3700Latest Information Update: 18 Apr 2023
At a glance
- Originator Kansas State University
- Developer Kansas State University; Tonix Pharmaceuticals Holding Corp
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 13 Mar 2023 Tonix Pharmaceuticals has PCT applications pending for TNX 3700
- 04 Jan 2022 Tonix Pharmaceuticals Holding Corp enters into an option and collaboration agreement with Kansas State University for TNX 3700 for COVID-2019 infections
- 04 Jan 2022 Preclinical trials in COVID-2019 infections (Prevention) in USA (Parenteral), prior to January 2022